Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Alessandro Esposito

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0079-2311; OpenAlex author ID A5054911905. Sources: OpenAlex.

Their work

Papers
23 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
97
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 3 papers · 2024: 3 papers · 2025: 4 papers · 2026: 4 papers

Papers 23

  1. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  2. Morphologic Characterization of Pancreatic Ductal Adenocarcinoma following Post-neoadjuvant Pancreatectomy and Clinical Value of Intratumor Heterogeneity. Co-author DOI 10.1097/sla.0000000000006565↗
  3. Interpreting Circulating Bile Acid Profiles in Pancreatic Cancer: The Role of Cholestasis and Its Management. First author DOI 10.3390/cancers18152481↗
  4. Correction: Danese et al. Interpreting Circulating Bile Acid Profiles in Pancreatic Cancer: The Role of Cholestasis and Its Management. Cancers 2026, 18, 2481. First author DOI 10.3390/cancers18193144↗
  5. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  6. Resection to Exploration Ratios and Associated Outcomes in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006197↗
  7. Reappraising the Role of Intraoperative Neck Margin Revision in Postneoadjuvant Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Multi-institution… Co-author DOI 10.1097/sla.0000000000006322↗
  8. Surgical and Oncological Outcomes of Minimally Invasive Left Pancreatectomy for Pancreatic Cancer: Robotic vs. Laparoscopic Approach. Last author DOI 10.3390/curroncol32070376↗
  9. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. Co-author DOI 10.1016/j.ejca.2023.113430↗
  10. The pan - COVID - AGICT study. The impact of COVID-19 pandemic on surgically treated pancreatic cancer patients. A multicentric Italian study. Co-author DOI 10.1016/j.suronc.2024.102081↗
  11. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  12. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  13. A dynamic analysis of empirical survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2022.11.015↗
  14. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  15. Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol. Co-author DOI 10.1245/s10434-022-11417-3↗
  16. Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver. Co-author DOI 10.1245/s10434-022-12385-4↗
  17. Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a Studies. Co-author DOI 10.1016/j.jss.2020.10.027↗
  18. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy i… Co-author DOI 10.1186/s12885-021-07877-7↗
  19. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  20. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Co-author DOI 10.1177/1758835920947969↗
  21. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2019.2277↗
  22. Minimally invasive surgery for pancreatic cancer. Co-author DOI 10.1080/14737140.2019.1685878↗
  23. Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. Co-author DOI 10.1016/j.pan.2018.04.002↗

Closest collaborators

The 25 strongest of 97 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Roberto Salvia · 16 shared papers, 2018–2026 · strength 2.52
  2. Matteo De Pastena · 11 shared papers, 2018–2026 · strength 1.97
  3. Gabriella Lionetto Lionetto · 9 shared papers, 2021–2026 · strength 1.94
  4. Giuseppe Malleo · 13 shared papers, 2018–2026 · strength 1.93
  5. Salvatore Paiella · 11 shared papers, 2018–2026 · strength 1.64
  6. Fabio Casciani · 6 shared papers, 2019–2026 · strength 1.14
  7. Claudio Bassi · 10 shared papers, 2018–2024 · strength 1.10
  8. Aldo Scarpa Scarpa · 6 shared papers, 2018–2026 · strength 0.95
  9. Antonio Pea · 4 shared papers, 2023–2026 · strength 0.90
  10. Claudio Luchini · 5 shared papers, 2022–2026 · strength 0.89
  11. Giuseppe Lippi · 2 shared papers, 2026 · strength 0.60
  12. Elisa Danese · 2 shared papers, 2026 · strength 0.60
  13. Giovanni Butturini · 5 shared papers, 2020–2024 · strength 0.60
  14. Mirko D’Onofrio · 5 shared papers, 2018–2024 · strength 0.46
  15. Giovanni Marchegiani · 5 shared papers, 2018–2024 · strength 0.45
  16. Paola Mattiolo · 2 shared papers, 2025–2026 · strength 0.44
  17. Laura Maggino · 4 shared papers, 2018–2023 · strength 0.43
  18. Davide Melisi · 4 shared papers, 2018–2024 · strength 0.35
  19. Erica Secchettin · 4 shared papers, 2018–2021 · strength 0.34
  20. Massimo Falconi · 2 shared papers, 2024–2025 · strength 0.33
  21. Massimiliano Tuveri · 4 shared papers, 2018–2021 · strength 0.30
  22. Valeria Merz · 3 shared papers, 2019–2024 · strength 0.29
  23. Tobias Keck · 2 shared papers, 2023–2024 · strength 0.25
  24. Riccardo Casadei · 2 shared papers, 2023–2024 · strength 0.25
  25. Andrea Pietrabissa · 2 shared papers, 2023–2024 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.